Drug Profile
VRDN 001
Alternative Names: Anti-IGF1R monoclonal antibody - Viridian Therapeutics; AVE 1642; VRDN-001; ZB 001Latest Information Update: 15 Feb 2024
Price :
$50
*
At a glance
- Originator ImmunoGen
- Developer sanofi-aventis; Viridian Therapeutics; Zenas BioPharma
- Class Antineoplastics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Insulin-like growth factor-I receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Graves ophthalmopathy
- Discontinued Breast cancer; Multiple myeloma; Solid tumours